The efficacy and safety of zoledronic acid and strontium-89 in treating non–small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
- 24 Downloads
Zoledronic acid (ZA) and strontium-89 have been widely used to treat lung cancer with bone metastases. The authors perform this meta-analysis to better evaluate the clinical outcome of ZA and strontium-89 for non–small cell lung cancer (NSCLC) patients.
We carried out standard meta-analysis and network meta-analysis based on a comprehensive data retrieval of EMBASE, PubMed, and Cochrane Library databases (up to March 2019). Random and fixed effects models were used where indicated and between-study heterogeneity was assessed. The primary endpoints were overall survival (OS) and skeletal-related events (SREs). The second endpoints were progression-free survival (PFS) and overall response rate (ORR).
Seven randomized clinical trials, including 1426 NSCLC patients with seven studies of zoledronic acid and two studies of strontium-89, met the inclusion criteria. Compared with the control group, ZA is associated with a OS benefit (1-year survival rate: RR = 1.76, 95% CI 1.36–2.27; and 24-month survival rate: RR = 2.38, 95% CI 1.35–4.19) and a reduction of SREs (RR = 0.57, 95% CI 0.40–0.84) for the patients with bone metastases. No statistical differences were found in PFS and ORR. Network meta-analysis for the patients with bone metastases showed that ZA + strontium-89 and ZA harbored significantly clinical benefits than strontium-89 and placebo in terms of 1-year survival rate and SREs. Both head-to-head study and network meta-analysis showed that strontium-89 had no statistical impact on OS and SREs compared with placebo.
Our analysis demonstrates that ZA +strontium-89 can be considered a priority for NSCLC patients with bone metastases, followed by ZA.
KeywordsZoledronic acid (ZA) Non small cell lung cancer Bone metastases Strontium-89
Non–small cell lung cancer
N-Telopeptide of type I collagen
Overall response rate
Z.G.H. and W.X.L. conceived the study and participated in the design. Y.S.R and Y.F T. collected the data. F.J.Z. performed statistical analyses. Z.G.H. drafted the manuscript. W.X.L. and Y.S.R helped to draft the manuscript. F.J.Z. revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.
Compliance with ethical standards
The authors declare that they have no conflict of interest.
- 5.Uemura H, Yanagisawa M, Ikeda I, Fujinami K, Iwasaki A, Noguchi S, Noguchi K, Kubota Y, Yokohama Bone Metastasis Study Group (2013) Possible anti-tumor activity of initial treatment with ZA with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol 18(3):472–477CrossRefGoogle Scholar
- 17.Li N, Yang Z, Chai H et al (2018) Clinical research of zoledronic acid and strontium-89in treatment of patients with asymptomatic bone metastases from non-small cell lung cancer. Chin J Cancer Prevent Treatment 25(13):962–967Google Scholar
- 19.Higgins JPT, Altman DG, Sterne JAC (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The cochrane collaboration. Available: https://www.cochranehandbook.org. Accessed 10 Oct 2012
- 22.Pandya KJ, Gajra A, Warsi GM, Argonza-Aviles E, Ericson SG, Wozniak AJ (2010) Multicenter, randomized, phase 2 study of Zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67(3):330–338CrossRefGoogle Scholar
- 24.Kritikos K, Heras P, Hatzopoulos A et al (2008) Efficacy and safety of intravenous zoledronic acid (ZA) 4 MG infused over 15 minutes: results from a 2-year study of lung cancer patients (LCP) with metastatic bone disease. Ann Oncol 19(S8):viii286–viii287Google Scholar
- 25.Tamiya M, Tokunaga S, Okada H, Suzuki H, Kobayashi M, Sasada S, Okamoto N, Morishita N, Matsuura Y, Miyamoto N, Hattori M, Taira K, Daga H, Takeda K, Hirashima T (2013) Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer. Clin Lung Cancer 14(4):364–369CrossRefGoogle Scholar
- 26.Tamiya M, Kobayashi M, Morimura O, Yasue T, Nakasuji T, Satomu M, Kohei O, Takayuki S, Morishita N, Suzuki H, Sasada S, Okamoto N, Hirashima T, Kawase I (2013) Clinical significance of the serum crosslinked N-telopeptide of type I collagen as a prognostic marker for non-small-cell lung cancer. Clin Lung Cancer 14(1):50–54CrossRefGoogle Scholar
- 27.Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving Zoledronic acid. Cancer 113(1):193–201CrossRefGoogle Scholar
- 32.Heianna J, Miyauchi T, Endo W et al (2014) Tumor regression of multiple bone metastases from breast cancer after administration of strontium-89 chloride (Metastron). Acta Radiol Short Rep 10(4):2047981613493412Google Scholar
- 36.Mhaskar R, Redzepovic J, Wheatley K et al (2012) Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 16:CD003188Google Scholar